%0 Journal Article %1 Rasmussen2018 %A Rasmussen, Lotte %A Pratt, Nicole %A Hansen, Morten Rix %A Hallas, Jesper %A Pottegård, Anton %D 2018 %J Pharmacoepidemiology and drug safety %K Kaplan-Meiersurvivalcurves drugutilization medicationpersistence pharmacoepidemiology proportionofpatientscovered survivalanalysis %N 8 %P 867-871 %R 10.1002/pds.4582 %T Using the "proportion of patients covered" and the Kaplan-Meier survival analysis to describe treatment persistence. %U http://doi.wiley.com/10.1002/pds.4582 http://www.ncbi.nlm.nih.gov/pubmed/29952045 %V 27 %X PURPOSE Standard Kaplan-Meier (KM) survival analysis is often used to study treatment persistence estimating the proportion of patients who have not yet experienced a treatment break by a given day after treatment initiation. This method only allows patients to be studied until their first treatment break. The "proportion of patients covered" (PPC) method is another approach to study treatment persistence. It measures the proportion of live patients currently covered by treatment. We aimed to describe the PPC method, show how the KM survival analysis and the PPC method can describe treatment persistence, and discuss the interpretation/application of the methods. METHODS We identified new users of statins, selective serotonin reuptake inhibitors, hormone replacement therapy, and ibuprofen. We used KM estimates and the PPC to describe persistence in the 3 years post treatment initiation, using a grace period of 90 days to define a treatment break. RESULTS Three years after statin initiation, approximately 40% of patients were still in continuous treatment (KM survival) and 60% of patients still alive were in current treatment (PPC). Corresponding numbers were 12% and 25% for selective serotonin reuptake inhibitors and 9% and 29% for hormone replacement therapy. At 1 year, numbers were 5% and 10% for ibuprofen. The PPC showed markedly less variability than the KM survival analysis with different choices of grace periods. CONCLUSIONS The KM survival analysis and the PPC method can be used to study different aspects of treatment persistence. Together, they provide a more complete picture of treatment persistence and drug use patterns.

@article{Rasmussen2018, abstract = {PURPOSE Standard Kaplan-Meier (KM) survival analysis is often used to study treatment persistence estimating the proportion of patients who have not yet experienced a treatment break by a given day after treatment initiation. This method only allows patients to be studied until their first treatment break. The "proportion of patients covered" (PPC) method is another approach to study treatment persistence. It measures the proportion of live patients currently covered by treatment. We aimed to describe the PPC method, show how the KM survival analysis and the PPC method can describe treatment persistence, and discuss the interpretation/application of the methods. METHODS We identified new users of statins, selective serotonin reuptake inhibitors, hormone replacement therapy, and ibuprofen. We used KM estimates and the PPC to describe persistence in the 3 years post treatment initiation, using a grace period of 90 days to define a treatment break. RESULTS Three years after statin initiation, approximately 40% of patients were still in continuous treatment (KM survival) and 60% of patients still alive were in current treatment (PPC). Corresponding numbers were 12% and 25% for selective serotonin reuptake inhibitors and 9% and 29% for hormone replacement therapy. At 1 year, numbers were 5% and 10% for ibuprofen. The PPC showed markedly less variability than the KM survival analysis with different choices of grace periods. CONCLUSIONS The KM survival analysis and the PPC method can be used to study different aspects of treatment persistence. Together, they provide a more complete picture of treatment persistence and drug use patterns.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Rasmussen, Lotte and Pratt, Nicole and Hansen, Morten Rix and Hallas, Jesper and Pottegård, Anton}, biburl = {https://www.bibsonomy.org/bibtex/210b7c1e217f803060368c9cae40ee32e/jepcastel}, doi = {10.1002/pds.4582}, interhash = {6c636a3827489a24e53b82fe9e13e00a}, intrahash = {10b7c1e217f803060368c9cae40ee32e}, issn = {1099-1557}, journal = {Pharmacoepidemiology and drug safety}, keywords = {Kaplan-Meiersurvivalcurves drugutilization medicationpersistence pharmacoepidemiology proportionofpatientscovered survivalanalysis}, month = {8}, note = {Adherence}, number = 8, pages = {867-871}, pmid = {29952045}, timestamp = {2023-02-03T11:44:35.000+0100}, title = {Using the "proportion of patients covered" and the Kaplan-Meier survival analysis to describe treatment persistence.}, url = {http://doi.wiley.com/10.1002/pds.4582 http://www.ncbi.nlm.nih.gov/pubmed/29952045}, volume = 27, year = 2018 }